Skip to contentI
IGC Pharma, Inc.
I
IGCIGC Pharma, Inc. Q3 2019 · 10-Q
Revenue$1.29M$1.29M+68.6% vs Q3 2018 Net Income-$1.15M-$1.15MN/M vs Q3 2018 EPS Diluted-$0.03-$0.03N/M vs Q3 2018 Gross Profit$45,000+15.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IGC Pharma, Inc. · CIK 1326205 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,331,000N/M Free Cash Flowderived-$1,335,000N/M Margins · derivedGross margin3.5%−1.6 pt vs Q3 2018
Operating margin-122.8%−60.7 pt vs Q3 2018
Net margin-89.3%−19.4 pt vs Q3 2018
ended Dec 31, 2018 · filed Feb 12, 2019 · 43 d after period end